Protecting Our Future
ReNewVax
Our aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines.
Protecting Our Future Through Vaccine Research
ReNewVax Ltd. is a University of Liverpool spin-out company co-founded by Dr Marie Yang and Prof Aras Kadioglu. The company was created through seed funding awarded by Innovate ICURe and funding from the University of Liverpool’s Enterprise Investment Fund. We aim to eliminate life-threatening bacterial infections and combat antimicrobial resistance with novel, broad coverage vaccines.
Vaccine Pipeline
RVX-001
Potentially first universal vaccine to Streptococcus pneumoniae (or pneumococcus)
- ReNewVax Ltd lead program
- A unique proprietary protein-based adjuvanted formulation
- Anticipate Phase 1 top line immunogenicity, safety and tolerability results in adults by end of 2025
RVX-002
Vaccine to Streptococcus agalactiae (or GBS)
- A rationally-designed vaccine candidate based on the analysis of over 15,000 publicly available genomes
- Initiated mRNA vaccinePOC/preclinical studies in Q1 2023
RVX-003
Vaccine to Streptococcus pyogenes (or GAS)
- Selection of final vaccine candidates expected in Q2 2023
Our Latest News
